1
|
Singh S, Drude N, Blank L, Desai PB, Königs H, Rütten S, Langen K, Möller M, Mottaghy FM, Morgenroth A. Protease Responsive Nanogels for Transcytosis across the Blood-Brain Barrier and Intracellular Delivery of Radiopharmaceuticals to Brain Tumor Cells. Adv Healthc Mater 2021; 10:e2100812. [PMID: 34490744 DOI: 10.1002/adhm.202100812] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 08/10/2021] [Indexed: 11/07/2022]
Abstract
Despite profound advances in treatment approaches, gliomas remain associated with very poor prognoses. The residual cells after incomplete resection often migrate and proliferate giving a seed for highly resistant gliomas. The efficacy of chemotherapeutic drugs is often strongly limited by their poor selectivity and the blood brain barrier (BBB). Therefore, the development of therapeutic carrier systems for efficient transport across the BBB and selective delivery to tumor cells remains one of the most complex problems facing molecular medicine and nano-biotechnology. To address this challenge, a stimuli sensitive nanogel is synthesized using pre-polymer approach for the effective delivery of nano-irradiation. The nanogels are cross-linked via matrix metalloproteinase (MMP-2,9) substrate and armed with Auger electron emitting drug 5-[125 I]Iodo-4"-thio-2"-deoxyuridine ([125 I]ITdU) which after release can be incorporated into the DNA of tumor cells. Functionalization with diphtheria toxin receptor ligand allows nanogel transcytosis across the BBB at tumor site. Functionalized nanogels efficiently and increasingly explore transcytosis via BBB co-cultured with glioblastoma cells. The subsequent nanogel degradation correlates with up-regulated MMP2/9. Released [125 I]ITdU follows the thymidine salvage pathway ending in its incorporation into the DNA of tumor cells. With this concept, a highly efficient strategy for intracellular delivery of radiopharmaceuticals across the challenging BBB is presented.
Collapse
Affiliation(s)
- Smriti Singh
- DWI–Leibniz Institute for Interactive Material Research RWTH Aachen University Aachen 52074 Germany
- Max Planck Institute for Medical Research Jahnstraße 29 Heidelberg 69120 Germany
| | - Natascha Drude
- DWI–Leibniz Institute for Interactive Material Research RWTH Aachen University Aachen 52074 Germany
- Department of Nuclear Medicine RWTH Aachen University Aachen 52074 Germany
| | - Lena Blank
- Department of Nuclear Medicine RWTH Aachen University Aachen 52074 Germany
| | - Prachi Bharat Desai
- DWI–Leibniz Institute for Interactive Material Research RWTH Aachen University Aachen 52074 Germany
| | - Hiltrud Königs
- Pathology–Department of Electron Microscopy RWTH Aachen University Aachen 52074 Germany
| | - Stephan Rütten
- Pathology–Department of Electron Microscopy RWTH Aachen University Aachen 52074 Germany
| | - Karl‐Josef Langen
- Department of Nuclear Medicine RWTH Aachen University Aachen 52074 Germany
- Institute of Neuroscience and Medicine Forschungszentrum Jülich Jülich 52428 Germany
| | - Martin Möller
- DWI–Leibniz Institute for Interactive Material Research RWTH Aachen University Aachen 52074 Germany
| | - Felix M. Mottaghy
- Department of Nuclear Medicine RWTH Aachen University Aachen 52074 Germany
- Department of Radiology and Nuclear Medicine Maastricht University Medical Center Maastricht 6229 HX The Netherlands
| | | |
Collapse
|
2
|
Lalier L, Mignard V, Joalland MP, Lanoé D, Cartron PF, Manon S, Vallette FM. TOM20-mediated transfer of Bcl2 from ER to MAM and mitochondria upon induction of apoptosis. Cell Death Dis 2021; 12:182. [PMID: 33589622 PMCID: PMC7884705 DOI: 10.1038/s41419-021-03471-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 01/11/2021] [Accepted: 01/21/2021] [Indexed: 12/20/2022]
Abstract
In this work, we have explored the subcellular localization of Bcl2, a major antiapoptotic protein. In U251 glioma cells, we found that Bcl2 is localized mainly in the ER and is translocated to MAM and mitochondria upon induction of apoptosis; this mitochondrial transfer was not restricted to the demonstrator cell line, even if cell-specific modulations exist. We found that the Bcl2/mitochondria interaction is controlled by TOM20, a protein that belongs to the protein import machinery of the mitochondrial outer membrane. The expression of a small domain of interaction of TOM20 with Bcl2 potentiates its anti-apoptotic properties, which suggests that the Bcl2–TOM20 interaction is proapoptotic. The role of MAM and TOM20 in Bcl2 apoptotic mitochondrial localization and function has been confirmed in a yeast model in which the ER–mitochondria encounter structure (ERMES) complex (required for MAM stability in yeast) has been disrupted. Bcl2–TOM20 interaction is thus an additional player in the control of apoptosis.
Collapse
Affiliation(s)
- Lisenn Lalier
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,LaBCT, ICO, Saint Herblain, France
| | - Vincent Mignard
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,LaBCT, ICO, Saint Herblain, France
| | - Marie-Pierre Joalland
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,LaBCT, ICO, Saint Herblain, France
| | - Didier Lanoé
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,LaBCT, ICO, Saint Herblain, France
| | - Pierre-François Cartron
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,LaBCT, ICO, Saint Herblain, France
| | - Stéphen Manon
- Institut de Biochimie et de Génétique Cellulaires, UMR 5095 CNRS & Université de Bordeaux, Bordeaux, France
| | - François M Vallette
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France. .,LaBCT, ICO, Saint Herblain, France.
| |
Collapse
|
3
|
Rabé M, Dumont S, Álvarez-Arenas A, Janati H, Belmonte-Beitia J, Calvo GF, Thibault-Carpentier C, Séry Q, Chauvin C, Joalland N, Briand F, Blandin S, Scotet E, Pecqueur C, Clairambault J, Oliver L, Perez-Garcia V, Nadaradjane A, Cartron PF, Gratas C, Vallette FM. Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death Dis 2020; 11:19. [PMID: 31907355 PMCID: PMC6944699 DOI: 10.1038/s41419-019-2200-2] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 12/05/2019] [Accepted: 12/05/2019] [Indexed: 12/17/2022]
Abstract
Drug resistance limits the therapeutic efficacy in cancers and leads to tumor recurrence through ill-defined mechanisms. Glioblastoma (GBM) are the deadliest brain tumors in adults. GBM, at diagnosis or after treatment, are resistant to temozolomide (TMZ), the standard chemotherapy. To better understand the acquisition of this resistance, we performed a longitudinal study, using a combination of mathematical models, RNA sequencing, single cell analyses, functional and drug assays in a human glioma cell line (U251). After an initial response characterized by cell death induction, cells entered a transient state defined by slow growth, a distinct morphology and a shift of metabolism. Specific genes expression associated to this population revealed chromatin remodeling. Indeed, the histone deacetylase inhibitor trichostatin (TSA), specifically eliminated this population and thus prevented the appearance of fast growing TMZ-resistant cells. In conclusion, we have identified in glioblastoma a population with tolerant-like features, which could constitute a therapeutic target.
Collapse
Affiliation(s)
- Marion Rabé
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Solenne Dumont
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,GenoBiRD, SFR François Bonamy, Université de Nantes, Nantes, France
| | - Arturo Álvarez-Arenas
- Department of Mathematics and MôLAB-Mathematical Oncology Laboratory, University of Castilla-la Mancha, Ciudad Real, Spain
| | - Hicham Janati
- Laboratoire Jacques-Louis Lions, Inria, Mamba team and Sorbonne Université, Paris 6, UPMC, Paris, France
| | - Juan Belmonte-Beitia
- Department of Mathematics and MôLAB-Mathematical Oncology Laboratory, University of Castilla-la Mancha, Ciudad Real, Spain
| | - Gabriel F Calvo
- Department of Mathematics and MôLAB-Mathematical Oncology Laboratory, University of Castilla-la Mancha, Ciudad Real, Spain
| | | | - Quentin Séry
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Laboratoire de Biologie des Cancers et Théranostic, Institut de Cancérologie de l'Ouest-St Herblain, 44805, Saint-Herblain, France
| | - Cynthia Chauvin
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Noémie Joalland
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Floriane Briand
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Stéphanie Blandin
- Plate-Forme MicroPICell, SFR François Bonamy, Université de Nantes, Nantes, France
| | - Emmanuel Scotet
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Claire Pecqueur
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - Jean Clairambault
- Laboratoire Jacques-Louis Lions, Inria, Mamba team and Sorbonne Université, Paris 6, UPMC, Paris, France
| | - Lisa Oliver
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,CHU Nantes, 44093, Nantes, France
| | - Victor Perez-Garcia
- Department of Mathematics and MôLAB-Mathematical Oncology Laboratory, University of Castilla-la Mancha, Ciudad Real, Spain
| | - Arulraj Nadaradjane
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Laboratoire de Biologie des Cancers et Théranostic, Institut de Cancérologie de l'Ouest-St Herblain, 44805, Saint-Herblain, France
| | - Pierre-François Cartron
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,Laboratoire de Biologie des Cancers et Théranostic, Institut de Cancérologie de l'Ouest-St Herblain, 44805, Saint-Herblain, France
| | - Catherine Gratas
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France. .,CHU Nantes, 44093, Nantes, France.
| | - François M Vallette
- CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France. .,Laboratoire de Biologie des Cancers et Théranostic, Institut de Cancérologie de l'Ouest-St Herblain, 44805, Saint-Herblain, France.
| |
Collapse
|